Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 1
Submit an article Journal homepage
127
Views
0
CrossRef citations to date
0
Altmetric
Review

Impaired Antigen Presentation in Neoplasia: Basic Mechanisms and Implications for Acute Myeloid Leukemia

Marvin M van Luijn1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center, Department of Hematology, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected];2 Department of Immunopathology, Sanquin Research & Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
,
Willemijn van den Ancker1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center, Department of Hematology, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
,
Martine ED Chamuleau1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center, Department of Hematology, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
,
Gert J Ossenkoppele1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center, Department of Hematology, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
,
S Marieke van Ham2 Department of Immunopathology, Sanquin Research & Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
&
Arjan A van de Loosdrecht1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center, Department of Hematology, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
Pages 85-97 | Published online: 17 Dec 2009

Bibliography

  • San Miguel JF , VidrialesMB, Lopez-BergesC et al.: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.Blood98 , 1746–1751 (2001).
  • Kern W , VoskovaD, SchochC et al.: Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.Blood104 , 3078–3085 (2004).
  • Ruggeri L , CapanniM, UrbaniE et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science295 , 2097–2100 (2002).
  • Ruggeri L , MancusiA, CapanniM et al.: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.Blood110 , 433–440 (2007).
  • Kolb HJ : Graft-versus-leukemia effects of transplantation and donor lymphocytes.Blood112 , 4371–4383 (2008).
  • Schmid C , LabopinM, NaglerA et al.: Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.J. Clin. Oncol.25 , 4938–4945 (2007).
  • Kolb HJ , SchattenbergA, GoldmanJM et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.Blood86 , 2041–2050 (1995).
  • Falkenburg JH , MarijtWA, HeemskerkMH, WillemzeR: Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.Curr. Opin. Hematol.9 , 497–502 (2002).
  • Greiner J , DohnerH, SchmittM: Cancer vaccines for patients with acute myeloid leukemia – definition of leukemia-associated antigens and current clinical protocols targeting these antigens.Haematologica91 , 1653–1661 (2006).
  • Dunn GP , BruceAT, IkedaH, OldLJ, SchreiberRD: Cancer immunoediting:from immunosurveillance to tumor escape.Nat. Immunol.3 , 991–998 (2002).
  • Chamuleau ME , van de Loosdrecht AA, Hess CJ et al.: High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica93 , 1894–1898 (2008).
  • Whiteway A , CorbettT, AndersonR, MacdonaldI, PrenticeHG: Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission.Br. J. Haematol.120 , 442–451 (2003).
  • Cheuk AT , GuinnBA: Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.Front. Biosci.13 , 2022–2029 (2008).
  • Houtenbos I , WestersTM, OssenkoppeleGJ, van de Loosdrecht AA: Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica91 , 348–355 (2006).
  • Li L , GiannopoulosK, ReinhardtP et al.: Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.Int. J. Oncol.28 , 855–861 (2006).
  • Smyth MJ , GodfreyDI, TrapaniJA: A fresh look at tumor immunosurveillance and immunotherapy.Nat. Immunol.2 , 293–299 (2001).
  • Knutson KL , DisisML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.Cancer Immunol. Immunother.54 , 721–728 (2005).
  • Kennedy R , CelisE: Multiple roles for CD4+ T cells in anti-tumor immune responses.Immunol. Rev.222 , 129–144 (2008).
  • Wieder T , BraumullerH, KneillingM, PichlerB, RockenM: T cell-mediated help against tumors.Cell Cycle7 , 2974–2977 (2008).
  • Driscoll J , GoldbergAL: The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins.J. Biol. Chem.265 , 4789–4792 (1990).
  • Neefjes JJ , MomburgF, HammerlingGJ: Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter.Science261 , 769–771 (1993).
  • Kanaseki T , BlanchardN, HammerGE, GonzalezF, ShastriN: ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum.Immunity25 , 795–806 (2006).
  • Cresswell P , BangiaN, DickT, DiedrichG: The nature of the MHC class I peptide loading complex.Immunol. Rev.172 , 21–28 (1999).
  • Huang AY , BruceAT, PardollDM, LevitskyHI: In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter.Immunity4 , 349–355 (1996).
  • Burgdorf S , ScholzC, KautzA, TampeR, KurtsC: Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation.Nat. Immunol.9 , 558–566 (2008).
  • Guermonprez P , SaveanuL, KleijmeerM et al.: ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells.Nature425 , 397–402 (2003).
  • Bougneres L , HelftJ, TiwariS et al.: A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells.Immunity31 , 232–244 (2009).
  • Shen L , SigalLJ, BoesM, RockKL: Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo.Immunity21 , 155–165 (2004).
  • Di Pucchio T , ChatterjeeB, Smed-SorensenA et al.: Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.Nat. Immunol.9 , 551–557 (2008).
  • Wolf PR , PloeghHL: How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway.Annu. Rev. Cell Dev. Biol.11 , 267–306 (1995).
  • Pieters J , BakkeO, DobbersteinB: The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail.J. Cell Sci.106(Pt 3) , 831–846 (1993).
  • Anderson MS , MillerJ: Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules.Proc. Natl Acad. Sci. USA89 , 2282–2286 (1992).
  • Romagnoli P , GermainRN: The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy.J. Exp. Med.180 , 1107–1113 (1994).
  • Sloan VS , CameronP, PorterG et al.: Mediation by HLA-DM of dissociation of peptides from HLA-DR.Nature375 , 802–806 (1995).
  • van Ham M , van Lith M, Lillemeier Bet al.: Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J. Exp. Med.191 , 1127–1136 (2000).
  • Dani A , ChaudhryA, MukherjeeP et al.: The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endolysosomal compartment.J. Cell Sci.117 , 4219–4230 (2004).
  • Dengjel J , SchoorO, FischerR et al.: Autophagy promotes MHC class II presentation of peptides from intracellular source proteins.Proc. Natl Acad. Sci. USA102 , 7922–7927 (2005).
  • Paludan C , SchmidD, LandthalerM et al.: Endogenous MHC class II processing of a viral nuclear antigen after autophagy.Science307 , 593–596 (2005).
  • Dorfel D , AppelS, Grunebach Fet al.: Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood105 , 3199–3205 (2005).
  • Nimmerjahn F , MilosevicS, BehrendsU et al.: Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy.Eur. J. Immunol.33 , 1250–1259 (2003).
  • Zhou D , LiP, LinY et al.: LAMP-2A facilitates MHC class II presentation of cytoplasmic antigens.Immunity22 , 571–581 (2005).
  • Crotzer VL , BlumJS: Cytosol tolysosome transport of intracellular antigens during immune surveillance.Traffic9 , 10–16 (2008).
  • Lich JD , ElliottJF, BlumJS: Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins.J. Exp. Med.191 , 1513–1524 (2000).
  • Tewari MK , SinnathambyG, RajagopalD, EisenlohrLC: A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent.Nat. Immunol.6 , 287–294 (2005).
  • Roche PA , CresswellP: Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding.Nature345 , 615–618 (1990).
  • Garrido F , Ruiz-CabelloF, CabreraT et al.: Implications for immunosurveillance of altered HLA class I phenotypes inhuman tumours.Immunol. Today18 , 89–95 (1997).
  • Garcia-Lora A , AlgarraI, GarridoF: MHC class I antigens, immune surveillance, and tumor immune escape.J. Cell. Physiol.195 , 346–355 (2003).
  • Serrano A , TanzarellaS, LionelloI et al.: Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2´-deoxycytidine treatment.Int. J. Cancer94 , 243–251 (2001).
  • Blanchet O , BourgeJF, ZinsznerH et al.: DNA binding of regulatory factors interacting with MHC-class-I gene enhancer correlates with MHC-class-I transcriptional level in class-I-defective cell lines.Int. J. Cancer Suppl.6 , 138–145 (1991).
  • Chang CC , CampoliM, RestifoNP, WangX, FerroneS: Immune selection of hot-spot b 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.J. Immunol.174 , 1462–1471 (2005).
  • Seliger B , MaeurerMJ, FerroneS: TAP off – tumors on.Immunol. Today18 , 292–299 (1997).
  • Jordanova ES , PhilippoK, GiphartMJ, SchuuringE, KluinPM: Mutations in the HLA class II genes leading toloss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma.Immunogenetics55 , 203–209 (2003).
  • van der Stoep N , BiestaP, QuintenE, van den Elsen PJ: Lack of IFN-γ-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int. J. Cancer97 , 501–507 (2002).
  • Campoli M , FerroneS: HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.Oncogene27 , 5869–5885 (2008).
  • Goldstein OG , HajiaghamohseniLM, AmriaS et al.: γ-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.Cancer Immunol. Immunother.57 , 1461–1470 (2008).
  • Lemaire G , GuittetO, VesinMF, LepoivreM, CottetMH: Glutathione depletion reveals impairment of antigen processing and inhibition of cathepsin activity by nitric oxide in antigen-presenting cells.Mol. Immunol.46 , 1100–1108 (2009).
  • Savoia P , D‘AlfonsoS, PeruccioD et al.: Loss of surface HLA class I molecules in leukemic myeloblasts is correlated with an increased leukocyte concentration at onset.Haematologica77 , 127–129 (1992).
  • Brouwer RE , van der HP, Schreuder GM et al.: Loss or downregulation of HLAclass I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum. Immunol.63 , 200–210 (2002).
  • Wetzler M , BaerMR, StewartSJ et al.: HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse.Leukemia15 , 128–133 (2001).
  • Masuda K , HirakiA, FujiiN et al.: Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts.Cancer Sci.98 , 102–108 (2007).
  • Vago L , PernaSK, ZanussiM et al.: Loss of mismatched HLA in leukemia after stem-cell transplantation.N. Engl. J. Med.361 , 478–488 (2009).
  • Majumder D , BandyopadhyayD, ChandraS et al.: Analysis of HLA class Ia transcripts in human leukaemias.Immunogenetics57 , 579–589 (2005).
  • Demanet C , MulderA, DeneysV et al.: Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?Blood103 , 3122–3130 (2004).
  • Wetzler M , McElwainBK, StewartCC et al.: HLA-DR antigen-negative acute myeloid leukemia.Leukemia17 , 707–715 (2003).
  • Chamuleau ME , SouwerY, van Ham SM et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res.64 , 5546–5550 (2004).
  • van Luijn, Chamuleau MED , ThompsonJA et al.: CLIP down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T cell responses. DOI:10.3324/haematol.2009.010595Haematologica (2009).
  • Armstrong TD , ClementsVK, MartinBK, TingJP, Ostrand-RosenbergS: Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.Proc. Natl Acad. Sci. USA94 , 6886–6891 (1997).
  • de Gruijl TD , van den Eertwegh AJ, Pinedo HM, Scheper RJ: Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother.57 , 1569–1577 (2008).
  • Westers TM , StamAG, ScheperRJ et al.: Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia.Cancer Immunol. Immunother.52 , 17–27 (2003).
  • Cheuk AT , ChanL, CzepulkowskiB et al.: Development of a whole cell vaccine for acute myeloid leukaemia.Cancer Immunol. Immunother.55 , 68–75 (2006).
  • Muhlethaler-Mottet A , OttenLA, SteimleV, MachB: Expression of MHC class II molecules in differentcellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.EMBO J.16 , 2851–2860 (1997).
  • Roucard C , ThomasC, PasquierMA et al.: In vivo and in vitro modulation of HLA-DM and HLA-DO is induced by B lymphocyte activation.J. Immunol.167 , 6849–6858 (2001).
  • Thompson JA , DissanayakeSK, KsanderBR et al.: Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.Cancer Res.66 , 1147–1154 (2006).
  • Thompson JA , SrivastavaMK, BoschJJ et al.: The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.Cancer Immunol. Immunother.57 , 389–398 (2008).
  • Setiadi AF , OmilusikK, DavidMD et al.: Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors.Cancer Res.68 , 9601–9607 (2008).
  • Khan AN , GregorieCJ, TomasiTB: Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.Cancer Immunol. Immunother.57 , 647–654 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.